

## Director/PDMR Shareholding

August 22, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG)

### Notification of transaction by person discharging managerial responsibilities

<b>1.</b>	<b>Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated them (“PCA”)</b>		
a)	Name	Flemming Ornskov	
<b>2.</b>	<b>Reason for the notification</b>		
a)	Position / status	Chief Executive Officer – PDMR	
b)	Initial notification / amendment	Initial notification	
<b>3.</b>	<b>Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	Shire plc	
b)	LEI	54930005LQRLI2UXRQ59	
<b>4.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument Identification code	Shire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)  ISIN: JE00B2QKY057	
b)	Nature of the transaction	Acquisition of Ordinary Shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£36.6493	8,400
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	August 22, 2017	
f)	Place of the transaction	London Stock Exchange	

Oliver Strawbridge  
Senior Assistant Company Secretary

**For further information please contact:**

**Investor Relations**

Ian Karp	<a href="mailto:ikarp@shire.com">ikarp@shire.com</a>	+1 781 482 9018
Robert Coates	<a href="mailto:rcoates@shire.com">rcoates@shire.com</a>	+44 1256 894874

**Media**

Lisa Adler	<a href="mailto:lisa.adler@shire.com">lisa.adler@shire.com</a>	+1 617 588 8607
Debbi Ford	<a href="mailto:debbi.ford@shire.com">debbi.ford@shire.com</a>	+1 617 949 9083

**NOTES TO EDITORS****About Shire**

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

[www.shire.com](http://www.shire.com)